cms.bioaccessla.com

Tag: cold chain

  • Radiopharma Trials In Latin America: Designing Operations For 6 Hour Half-Lives

    Radiopharma Trials in Latin America: Designing Operations for 6-Hour Half-Lives

    Primary keyword: radiopharmaceutical clinical trial logistics Latin America

    Radiopharmaceuticals are one of the most promising frontiers in oncology, but they force clinical teams to operate on a different clock. An industry announcement noted that because these materials decay in hours rather than months, the operational window for patient administration is extremely narrow, leaving very little margin for error.

    Latin America can be an attractive region for radiopharma development, but sponsors need an operating model that is designed for short half-lives, just-in-time supply, and site readiness. This article outlines a practical framework for radiopharmaceutical clinical trial logistics in Latin America—without duplicating country-specific checklists already covered elsewhere.

    1) Start with the “decay clock” and design backward

    Radiopharma operations should start with physics. If a product’s usable window is measured in hours, then every downstream step must be planned backwards from the scheduled administration time:

    • Manufacturing slot and release testing (including potential rework)
    • Packaging and validated temperature control
    • Transportation and customs risk (for cross-border moves)
    • Site receipt, verification, and patient preparation

    Operational principle: Do not treat shipment as a “logistics problem.” Treat it as part of the dosing procedure.

    2) Build site readiness around minute-by-minute workflows

    In many conventional trials, small workflow inefficiencies are tolerated. In radiopharma, they can cause missed windows or protocol deviations.

    • Define a standard receiving workflow: who signs, where it is stored, and how identity and activity are verified.
    • Train for exceptions: delayed flights, partial shipments, or last-minute patient rescheduling.
    • Synchronize departments: nuclear medicine, pharmacy, imaging, and the clinical team must share one operational plan.

    3) Manage supply risk with redundancy and “plan B” lanes

    A radiopharma webinar announcement highlighted just-in-time manufacturing and strict cold-chain requirements as differentiators from standard investigational products, and emphasized that protocol pivots and supply disruptions are expected rather than rare. In Latin America, the right mitigation strategies can include:

    • Backup transport lanes: pre-qualified couriers and alternate airport routing options.
    • Site network design: cluster sites to reduce travel time from production to administration.
    • Inventory philosophy: you cannot “stockpile” short half-life product, so redundancy must come from operations, not storage.

    4) A practical operating model for Latin America radiopharma programs

    To make logistics predictable, sponsors can standardize four elements across countries:

    • Readiness checklists: site staffing, equipment calibration, temperature monitoring, and emergency procedures.
    • Scheduling discipline: patient scheduling should be tied to confirmed manufacturing slots and transport windows.
    • Visibility: live tracking of manufacturing status, shipment milestones, and site receipt confirmation.
    • Contingency triggers: pre-defined thresholds for when to reschedule a patient, re-route a shipment, or activate an alternate site.

    When these elements are standardized, the operational advantage of Latin America—experienced research sites and growing infrastructure—can translate into reliable execution, not just theoretical speed.

    5) Data integrity and chain-of-custody: treat the dose as a specimen

    With radiopharmaceuticals, sponsors should document the product journey with the same rigor used for biospecimens. This reduces deviations and supports inspection readiness.

    • Time-stamped handoffs: manufacturing release, courier pickup, arrival at site, and administration time.
    • Temperature and shielding logs: continuous monitoring, out-of-range triggers, and documented corrective actions.
    • Identity checks: verify patient, product label, and activity at the moment of administration.

    Practical tip: Create a single-page “dose administration record” that sites can complete in real time and upload the same day.

    6) Regulatory and customs planning: design for border reality

    Latin America is not one regulatory system. Cross-border moves can introduce unpredictable delays, so logistics planning should assume variability and reduce exposure wherever possible.

    • Prefer in-country or near-country production when feasible: shorter transit times reduce decay loss.
    • Pre-clear documentation: align on import documentation, labeling, and receiver information well before first shipment.
    • Schedule around local constraints: weekends, holidays, and airport cutoffs matter more when the product lifetime is measured in hours.

    When sponsors plan for these constraints, Latin America sites can deliver high-quality execution even for time-sensitive protocols.

    FAQ: Radiopharmaceutical clinical trial logistics Latin America

    • Why are radiopharmaceutical trials harder to run than conventional trials?
      Because many products decay in hours, the operational window is extremely narrow and sites must coordinate manufacturing, shipping, and patient readiness with little margin for error.
    • What is the most common operational failure mode?
      Missed administration windows caused by delays in manufacturing release, transportation, site workflow issues, or patient no-shows.
    • How can Latin America sites reduce missed dosing windows?
      By building standardized readiness checklists, aligning patient scheduling with shipment timelines, and designing contingency plans for transportation or manufacturing disruptions.

    Planning a radiopharma study in Latin America? bioaccess® can help sponsors design site networks, readiness plans, and startup execution models that reduce missed dosing windows.

  • Importer of Record (IOR) for Multi‑Country MedTech Trials in Latin America: A Sponsor‑Ready Playbook

    Importer of Record (IOR) for Multi‑Country MedTech Trials in Latin America: A Sponsor‑Ready Playbook

    In Latin America, getting a first-in-human or early-stage MedTech study approved is only half the battle. The other half is operational: getting investigational devices, accessories, and consumables through customs reliably—on time, every time, across multiple countries.

    That is why the Importer of Record (IOR) decision becomes a critical-path item for sponsors. An IOR strategy is not just “paperwork.” It is the control system that determines who is legally responsible for the import, who holds product registrations (when needed), how the shipment is classified, and who can react when a package is held.

    This playbook explains what an IOR does in the context of MedTech clinical trials in Latin America, how to choose an IOR model for multi-country programs, and which checklists reduce the most common causes of delays.

    What is an Importer of Record (IOR) in a clinical trial context?

    An Importer of Record is the entity that assumes legal responsibility for bringing goods into a country. In MedTech clinical trials, the IOR is typically responsible for:

    • Customs declaration and classification (HS codes, declared value, product description consistency)
    • Regulatory alignment for investigational-use shipments (where applicable)
    • Coordination with brokers and resolution of holds, inspections, and documentation requests
    • Chain-of-custody documentation and receiving confirmation for sites
    • Import compliance (licenses, tax IDs, authorizations, and record retention)

    For a sponsor running a multi-country LATAM program, the IOR is a practical risk owner: when the shipment is delayed, the IOR is the party with standing to respond, correct documents, and release the goods.

    Why the IOR decision becomes a critical path in Latin America

    Multi-country execution introduces parallel risk. Even if each country has a clean regulatory path, supply chain variability can create staggered site activations and missed enrollment windows. Common delay drivers include:

    • Inconsistent product descriptions between invoice, packing list, airway bill, and regulatory letters
    • Misaligned declared value (e.g., “free of charge” shipments that trigger valuation questions)
    • Unclear purpose-of-import (commercial vs investigational vs donation terminology)
    • Missing or outdated IOR registrations (tax IDs, legal entity status, import licenses)
    • Cold chain ambiguity (temperature ranges not specified, packaging validation gaps)

    The impact is rarely isolated. A single held shipment can create a cascade: rescheduled site initiation visits, re-booked monitoring travel, delayed training, and protocol deviations when replacement components arrive late.

    IOR models for multi-country LATAM MedTech trials (and how to choose)

    There is no universal best model. The right answer depends on the investigational product profile, the number of countries, and how much operational control the sponsor needs.

    Model A: Site or hospital as IOR

    When it works: small studies, low-complexity devices, and highly experienced research institutions with established import processes.

    Risks: sites often lack bandwidth for repeated customs interactions; import experience varies widely; accountability becomes fragmented across countries.

    Model B: Local distributor as IOR

    When it works: later-stage programs where a commercial partner already exists and can support consistent import flows.

    Risks: distributor incentives may not match trial urgency; conflict may arise around product classification, pricing, or future commercial rights.

    Model C: Sponsor-appointed specialized IOR/clinical logistics partner

    When it works: multi-country studies, time-sensitive shipments, accessory-heavy devices, and programs requiring consistent compliance documentation.

    Benefits: centralized process control, repeatable templates, proactive broker management, and stronger visibility across the supply chain.

    Sponsor selection criteria should include: country coverage, medical product import track record, temperature-controlled capability (if relevant), speed of document turnaround, and documented escalation procedures.

    The sponsor-ready IOR checklist (what to confirm before first shipment)

    • Legal entity readiness: confirm the IOR’s legal registration, tax identifiers, and ability to act as importer for investigational medical products.
    • Defined shipment purpose language: use consistent terms such as “investigational-use medical device for clinical study” and avoid mixed commercial language.
    • Standard document pack: commercial invoice (even if no charge), packing list, airway bill, letter of authorization, and study documentation as required.
    • HS code governance: lock a primary HS classification per SKU/component and document the rationale for re-use across shipments.
    • Broker alignment: confirm who the broker is, how communications flow, and who can approve changes under time pressure.
    • Receiving plan: define site receiving hours, quarantine process (if any), and confirmation steps to close the logistics loop.

    In multi-country programs, treat this checklist as a controlled document. Once validated, it becomes the baseline for every country pack with only country-specific annexes.

    How to reduce customs holds and avoid “silent delays”

    Many delays occur because the sponsor does not hear about an issue until the shipment has already been held for days. Reduce that risk with:

    • Pre-alerts: send document packs to the IOR/broker before shipment departure for pre-review.
    • Single source of truth: maintain a shipment register shared with the IOR and the clinical team (SKU, lot/serial ranges, destination sites, temperature requirements).
    • Escalation SLAs: require response times for holds (e.g., 2–4 hours during business days) and define who can approve revised declarations.
    • Component rationalization: where possible, reduce “mixed shipments” with many line items that increase classification complexity.

    Sponsors should also build a buffer into the activation plan. Even with a strong IOR, variability exists. The objective is not perfection; it is predictable, recoverable execution.

    FAQ

    Do we need one IOR per country for a multi-country LATAM trial?

    Yes—imports occur at the country level, so each country requires an importer. The strategic decision is whether to use the same specialized partner (with local entities) across countries to standardize documentation and escalation.

    Can we ship devices as “no commercial value” to simplify customs?

    Not necessarily. “No commercial value” language can trigger valuation questions. A clearer approach is to declare an appropriate value and describe the purpose consistently as investigational-use for a clinical study.

    What should sponsors measure to manage IOR performance?

    Track time from shipment tender to customs release, number of holds per shipment, root causes of holds, and time-to-response during escalation. These metrics quickly reveal whether the IOR process is improving or drifting.

    Bottom line: In Latin America, the IOR model is a study design decision as much as an operations decision. Define it early, standardize it across countries, and your activation timeline becomes far more reliable.

  • Radiopharmaceutical Trials in Latin America: Logistics That Make or Break Your First Patient In

    Radiopharmaceutical Trials in Latin America: Logistics That Make or Break Your First Patient In

    Radiopharmaceutical clinical trials behave differently from most other clinical programs. The “product” is not just a vial—it is a time-sensitive system that includes isotope production, radiolabeling, quality control (QC), packaging, cross-border movement, and last-mile delivery to the imaging suite or treatment room. The most successful programs design these constraints into the protocol from day one.

    Across Latin America, sponsors can unlock faster activation and access to experienced nuclear medicine teams, but they also face logistical realities: variable availability of isotopes, airport cargo limitations, customs clearance variability, and the physics of radioactive decay. A 2026 Pharmaphorum analysis emphasizes that short half-lives require carefully managed distribution, compliance with strict international regulations, specialized packaging, and in some cases decentralized or local radiolabeling rather than centralized manufacturing.

    This article outlines a logistics-first playbook for radiopharmaceutical trials in Latin America, focusing on practical steps that protect schedule, quality, and patient safety without disclosing confidential sponsor details.

    Start with physics: half-life drives everything

    The logistics challenge scales with how quickly your isotope loses usable activity. Pharmaphorum highlights that some isotopes used in radiotherapeutics have very different half-lives, including approximately 6.7 days for Lu-177 and about 10.6 hours for Pb-212. When half-life is short, “time in transit” becomes a clinical performance variable, not merely an operational cost.

    Implication: your trial design must specify not only dose and administration, but also supply chain constraints such as maximum transport duration, acceptable activity range at administration, and contingencies when shipments miss the window.

    Design the supply chain as part of the protocol

    In radiopharma, supply chain and protocol are inseparable. The Pharmaphorum article notes that shipping requires compliance with strict international regulations and specialized packaging. Sponsors should treat packaging qualification, lane qualification, and customs planning as protocol-enabling activities.

    • Define the chain of custody: who releases the batch, who transports it, and who receives it at the site.
    • Define time stamps: end of synthesis, QC release, handoff to carrier, arrival at airport, customs release, receipt at site, administration time.
    • Define acceptance criteria: activity at administration, sterility assurance approach, and temperature/shielding requirements.

    Common pitfall: a protocol that assumes a “normal” drug supply chain will often fail on the first shipment because radiopharma realities (lane availability, airline acceptance, customs timing) were not operationalized.

    Import and transport compliance: plan lead times early

    Cross-border movement of radioactive materials is governed by multiple layers of regulation. Even outside Latin America, the U.S. Department of Transportation’s 49 CFR §173.476 illustrates the compliance mindset regulators expect: offerors must maintain a safety analysis and documentation of tests demonstrating compliance, and certificate requests may need to be received at least 90 days before the requested effective date. The details differ by jurisdiction, but the principle is consistent—radiopharma transport is a regulated process with non-trivial lead times.

    Practical takeaway for LATAM trials: build an “import and transport readiness calendar” that starts months before first patient in. If you wait until sites are activated to address permits and transport documentation, your trial will be delayed even if the science is ready.

    Decentralized radiolabeling: when local production beats centralization

    One of the most important insights from Pharmaphorum is that short-half-life isotopes can force local radiolabeling. The article explains that while longer half-life isotopes can be labeled in centralized facilities, Pb-212’s shorter half-life necessitates local radiolabeling and therefore a wider geographic footprint. This is a strategic decision: do you build a hub-and-spoke network, partner with regional capabilities, or choose an isotope/asset combination that is more forgiving for your operational footprint?

    • Hub-and-spoke model: install generator or labeling capability in a regional hub and distribute doses to nearby sites.
    • Site-embedded model: enable radiolabeling at select high-capability hospitals.
    • Hybrid model: start with one hub for early-phase feasibility, then expand regionally as you scale enrollment.

    Key decision criterion: the relationship between half-life, flight schedules, customs predictability, and on-site capacity to release product to patients.

    Operational playbook: a 10-point readiness checklist

    • 1) Lane qualification: choose airports and carriers that routinely accept radioactive cargo and can document handling.
    • 2) Packaging validation: confirm shielding, labeling, and any required temperature control under realistic transit times.
    • 3) QC release plan: clarify which tests are performed before shipment vs. at/near site, and how results are documented.
    • 4) Customs “fast track” alignment: prepare documentation so the shipment’s purpose and classification are unambiguous.
    • 5) Missed-window contingency: define what happens if activity is below threshold at arrival.
    • 6) Scheduling discipline: align patient visits, imaging slots, and dosing windows to inbound shipment timing.
    • 7) Training: ensure site staff understand receipt, storage, radiation safety basics, and administration workflows.
    • 8) Data capture: capture time stamps and activity measurements as structured data for operational learning.
    • 9) Vendor oversight: manage carriers and depots like critical clinical vendors, not like routine couriers.
    • 10) Scale strategy: expand to new countries only after proving repeatable shipment-to-administration performance.

    FAQ

    1) What is the biggest logistics risk in radiopharmaceutical clinical trials?

    For many programs, the biggest risk is the mismatch between isotope half-life and real-world transit time. If the product loses activity before administration, schedule and enrollment are immediately impacted.

    2) When is local radiolabeling necessary?

    Pharmaphorum notes that for very short half-life isotopes such as Pb-212 (about 10.6 hours), local radiolabeling may be necessary because centralized labeling can be incompatible with transit time and decay.

    3) How should sponsors plan for regulatory transport requirements?

    Start early and assume non-trivial lead times. Regulations like 49 CFR §173.476 show that authorities expect documented safety analyses and, in some cases, certificate requests planned months in advance. Use that mindset to build a transport-ready process tailored to each participating LATAM jurisdiction.

    Educational content only. Sponsors should consult qualified radiopharmaceutical manufacturing, logistics, and regulatory experts for trial-specific requirements.

  • Radiopharma Trials In Latin America: Designing Operations For 6 Hour Half-Lives

    Radiopharma Trials in Latin America: Designing Operations for 6-Hour Half-Lives

    Primary keyword: radiopharmaceutical clinical trial logistics Latin America

    Radiopharmaceuticals are one of the most promising frontiers in oncology, but they force clinical teams to operate on a different clock. An industry announcement noted that because these materials decay in hours rather than months, the operational window for patient administration is extremely narrow, leaving very little margin for error.

    Latin America can be an attractive region for radiopharma development, but sponsors need an operating model that is designed for short half-lives, just-in-time supply, and site readiness. This article outlines a practical framework for radiopharmaceutical clinical trial logistics in Latin America—without duplicating country-specific checklists already covered elsewhere.

    1) Start with the “decay clock” and design backward

    Radiopharma operations should start with physics. If a product’s usable window is measured in hours, then every downstream step must be planned backwards from the scheduled administration time:

    • Manufacturing slot and release testing (including potential rework)
    • Packaging and validated temperature control
    • Transportation and customs risk (for cross-border moves)
    • Site receipt, verification, and patient preparation

    Operational principle: Do not treat shipment as a “logistics problem.” Treat it as part of the dosing procedure.

    2) Build site readiness around minute-by-minute workflows

    In many conventional trials, small workflow inefficiencies are tolerated. In radiopharma, they can cause missed windows or protocol deviations.

    • Define a standard receiving workflow: who signs, where it is stored, and how identity and activity are verified.
    • Train for exceptions: delayed flights, partial shipments, or last-minute patient rescheduling.
    • Synchronize departments: nuclear medicine, pharmacy, imaging, and the clinical team must share one operational plan.

    3) Manage supply risk with redundancy and “plan B” lanes

    A radiopharma webinar announcement highlighted just-in-time manufacturing and strict cold-chain requirements as differentiators from standard investigational products, and emphasized that protocol pivots and supply disruptions are expected rather than rare. In Latin America, the right mitigation strategies can include:

    • Backup transport lanes: pre-qualified couriers and alternate airport routing options.
    • Site network design: cluster sites to reduce travel time from production to administration.
    • Inventory philosophy: you cannot “stockpile” short half-life product, so redundancy must come from operations, not storage.

    4) A practical operating model for Latin America radiopharma programs

    To make logistics predictable, sponsors can standardize four elements across countries:

    • Readiness checklists: site staffing, equipment calibration, temperature monitoring, and emergency procedures.
    • Scheduling discipline: patient scheduling should be tied to confirmed manufacturing slots and transport windows.
    • Visibility: live tracking of manufacturing status, shipment milestones, and site receipt confirmation.
    • Contingency triggers: pre-defined thresholds for when to reschedule a patient, re-route a shipment, or activate an alternate site.

    When these elements are standardized, the operational advantage of Latin America—experienced research sites and growing infrastructure—can translate into reliable execution, not just theoretical speed.

    5) Data integrity and chain-of-custody: treat the dose as a specimen

    With radiopharmaceuticals, sponsors should document the product journey with the same rigor used for biospecimens. This reduces deviations and supports inspection readiness.

    • Time-stamped handoffs: manufacturing release, courier pickup, arrival at site, and administration time.
    • Temperature and shielding logs: continuous monitoring, out-of-range triggers, and documented corrective actions.
    • Identity checks: verify patient, product label, and activity at the moment of administration.

    Practical tip: Create a single-page “dose administration record” that sites can complete in real time and upload the same day.

    6) Regulatory and customs planning: design for border reality

    Latin America is not one regulatory system. Cross-border moves can introduce unpredictable delays, so logistics planning should assume variability and reduce exposure wherever possible.

    • Prefer in-country or near-country production when feasible: shorter transit times reduce decay loss.
    • Pre-clear documentation: align on import documentation, labeling, and receiver information well before first shipment.
    • Schedule around local constraints: weekends, holidays, and airport cutoffs matter more when the product lifetime is measured in hours.

    When sponsors plan for these constraints, Latin America sites can deliver high-quality execution even for time-sensitive protocols.

    FAQ: Radiopharmaceutical clinical trial logistics Latin America

    • Why are radiopharmaceutical trials harder to run than conventional trials?
      Because many products decay in hours, the operational window is extremely narrow and sites must coordinate manufacturing, shipping, and patient readiness with little margin for error.
    • What is the most common operational failure mode?
      Missed administration windows caused by delays in manufacturing release, transportation, site workflow issues, or patient no-shows.
    • How can Latin America sites reduce missed dosing windows?
      By building standardized readiness checklists, aligning patient scheduling with shipment timelines, and designing contingency plans for transportation or manufacturing disruptions.

    Planning a radiopharma study in Latin America? bioaccess® can help sponsors design site networks, readiness plans, and startup execution models that reduce missed dosing windows.